A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer (DAHLIA)
A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Québec, Canada, H4A3J1
- Recruiting
- McGill University Health Centre (MUHC) - The Montreal
-
Contact:
- Phuong-nam Nguyen
- Phone Number: 5149341934
- Email: Phuong-nam.Nguyen@muhc.mcgill.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X6
- Recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Anh Nguyen
- Phone Number: 416-946-4501
- Email: anh.nguyen2@uhn.ca
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Contact:
- Mihae Song
- Phone Number: 877-467-3411
- Email: misong@coh.org
-
Santa Monica, California, United States, 90403
- Recruiting
- Sarcoma Oncology Research Center
-
Contact:
- Victoria Chua
- Phone Number: 310-552-9999
- Email: chua@sarcomaonology.com
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Jessica Grenbenc
- Phone Number: 216-444-7923
- Email: canceranswer@ccf.org
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Withdrawn
- SCRI Oncology Partners - PPDS
-
-
Utah
-
West Valley City, Utah, United States, 84119
- Recruiting
- START Mountain Region
-
Contact:
- Marie Asay
- Phone Number: 801-907-4750
- Email: marie.asay@startresearch.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
- Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
- Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
- Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)
Exclusion Criteria:
- Received treatment with another RBM39 degrader
- Clinically significant gastrointestinal (GI) or GI malabsorption
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 1a
Dose Finding
|
Oral
|
|
Experimental: Phase 1b Cohort A
|
Oral
|
|
Experimental: Phase 1b Cohort B
|
Oral
|
|
Experimental: Phase 1b Cohort C
|
Oral
|
|
Experimental: Phase 1b Cohort D
|
Oral
|
|
Experimental: Phase 2 Cohort 1 Dose #1
|
Oral
|
|
Experimental: Phase 2 Cohort 1 Dose #2
|
Oral
|
|
Experimental: Phase 2 Cohort 2 Dose #1
|
Oral
|
|
Experimental: Phase 2 Cohort 2 Dose #2
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 2- Objective Response Rate (ORR)
Time Frame: Initiation from study drug until disease progression (up to approximately 24 months)
|
To assess tumor response
|
Initiation from study drug until disease progression (up to approximately 24 months)
|
|
Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
Time Frame: Initiation of study drug through 4 weeks
|
To characterize the incidence of DLTs
|
Initiation of study drug through 4 weeks
|
|
Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse Event
Time Frame: Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
|
To characterize the incidence of treatment emergent adverse events
|
Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 1- ORR
Time Frame: Initiation from study drug until disease progression (up to approximately 24 months)
|
To assess tumor response
|
Initiation from study drug until disease progression (up to approximately 24 months)
|
|
Phase 1 and 2- Disease Control Rate (DCR)
Time Frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
To assess the anti-tumor activity
|
Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
|
Phase 1 and 2 - Duration of Response (DOR)
Time Frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
To assess the anti-tumor activity
|
Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
|
Phase 1 and 2 - Duration of Stable Disease (SD)
Time Frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
To assess the anti-tumor activity
|
Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
|
Phase 1 and 2 - Time to Response (TTR)
Time Frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
To assess the anti-tumor activity
|
Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
|
Phase 1 and 2 - Progression Free Survival (PFS)
Time Frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
To assess the anti-tumor activity
|
Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
|
Phase 1 and 2 - Overall Survival (OS)
Time Frame: Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
To assess the anti-tumor activity
|
Initiation from study drug until disease progression as applicable (up to approximately 24 months)
|
|
Phase 1 - Maximum Plasma Concentration (Cmax)
Time Frame: Initiation of study drug through Week 9
|
To characterize PK of REC-1245
|
Initiation of study drug through Week 9
|
|
Phase 1 - Time to Reach Maximum Plasma Concentration (Tmax)
Time Frame: Initiation of study drug through Week 9
|
To characterize PK of REC-1245
|
Initiation of study drug through Week 9
|
|
Phase 1 - Plasma Concentration Before the Next Dose (Ctrough)
Time Frame: Initiation of study drug through Week 9
|
To characterize PK of REC-1245
|
Initiation of study drug through Week 9
|
|
Phase 1 - Area Under Plasma Concentration-time Curve (AUC)
Time Frame: Initiation of study drug through Week 9
|
To characterize PK of REC-1245
|
Initiation of study drug through Week 9
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REC-1245-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.